Stem cells injected into brain of Alzheimer’s patients in world first - The Telegraph

Direct Source Verification: This story is aggregated from The Telegraph (telegraph.co.uk). Full reporting rights and copyright belong to the primary publisher.
Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

Alzheimer’s patients have had stem cells injected into their brains in a radical attempt to treat the disease.

The pioneering treatment aims to repair damage to the brain itself, rather than simply removing the harmful proteins associated with Alzheimer’s.

Experts said the findings from the first human trial, where stem cells were taken from their body fat, were a “very encouraging” breakthrough in the search for a cure.

In an initial trial involving six patients, five showed improvements on a standard test of memory and thinking following a single injection.

Brain scans suggested a reduction in amyloid plaques, while tests of spinal fluid found improvements in markers associated with Alzheimer’s.

Researchers said the findings were encouraging, although the study was too small to establish whether the treatment worked, and the early cognitive improvements were not sustained over the full year of follow-up.

The approach was presented at the Clinical Trials on Alzheimer’s Disease conference in Boston by Dr Christopher Duma, a US neurosurgeon with more than 30 years’ experience.

Dr Duma, medical director of the brain tumour programme at Hoag Memorial Presbyterian Hospital in Newport Beach, California, founded Regeneration Biomedical in 2018 to develop the treatment.

Dr Christopher Duma presented the findings at a conference in Boston Credit: Linkedin Unlike existing Alzheimer’s drugs, which target amyloid plaques, the experimental therapy aims to tackle several of the processes involved in the destruction of brain cells.

Scientists believe Alzheimer’s is driven by a combination of harmful protein accumulation, inflammation, damage to connections between brain cells, and ultimately the death of neurons.

Dr Duma suggested stem cells could potentially address several of these processes simultaneously.

“After all, a stem cell is nature’s pharmacy,” he told delegates.

Stem cells are a blank canvas which can become almost any type of tissue in the human body and can release chemicals which also protect other cells, regulate inflammation and encourage tissue repair.

Dr Duma’s treatment uses stem cells harvested from patients’ own fat through liposuction, avoiding the need for donor cells.

The cells are grown and multiplied in a laboratory for approximately two weeks, with researchers selecting those expressing a protein called Wnt, which is involved in cell growth and repair. The cells are not genetically modified.

They are then injected into fluid-filled spaces inside the brain, through a small reservoir implanted beneath the scalp.

Dr Duma likened the device, known as an Ommaya reservoir, to the ports used to deliver repeated treatments to cancer patients.

“I’m a neurosurgeon; that’s my day job. So, putting things in the brain was not a big task for me,” he said.

The device also allows repeated injections without further brain surgery.

Researchers hope that delivering stem cells directly into the brain will stimulate the body’s own repair mechanisms, potentially encouraging existing neural stem cells to become more active.

The phase one trial involved six patients with Alzheimer’s, who received either two million or five million cells.

All had evidence of amyloid accumulation, and underwent follow-up assessments over 12 months.

Five of the six showed cognitive improvements 12 weeks after treatment when measured on the Alzheimer’s Disease Assessment Scale, a standard test of memory and thinking.

Brain scans at 12 weeks also suggested a 23.6 per cent reduction in amyloid, while levels of phosphorylated tau, another protein associated with Alzheimer’s, remained reduced at the end of the year.

Researchers also reported improvements in other biological markers associated with nerve cell damage.

Dr Duma suggested that the falloff in the improvement in the following year could reflect the fact that patients had received only one injection.

No adverse events were recorded in the six patients during the trial, but experts warned the findings remain highly preliminary.

Without a placebo group, it is impossible to determine whether the changes were caused by the treatment, and there is no proof that the injections regenerated brain cells or slowed Alzheimer’s progression.

Dr Duma acknowledged that researchers did not yet understand precisely how the treatment might work.

“We have no idea how it really works,” he told delegates, suggesting several possible biological mechanisms were being investigated.

The US Food and Drug Administration has granted the programme fast-track designation, intended to support the development of treatments for serious conditions with unmet medical needs.

A larger phase two trial has received regulatory clearance and will investigate whether repeated treatment produces more sustained benefits.

Patients will receive injections every two months for a year, followed by four months of monitoring.

The approach represents a striking departure from the first generation of Alzheimer’s treatments, which work by clearing amyloid plaques from the brain.

Scientists are increasingly exploring whether tackling inflammation, tau tangles and other forms of brain damage could provide additional benefits.

But while stem cell treatment offers the possibility of addressing several disease processes at once, much larger controlled trials will be needed to establish whether it can deliver meaningful improvements for patients.

Dr Katharina Cosker, research programmes manager at Alzheimer’s Research UK, said: “The first human trial of a potential stem cell treatment has delivered very encouraging early findings.

“Not only has it appeared safe in patients, but researchers have also reported some promising changes in Alzheimer’s-related biomarkers. It’s an exciting start, but there’s much more to learn.

“The move towards Phase 2 is an important milestone. The next step is to establish whether these early findings translate into meaningful and sustained benefits for patients.

“Not long ago, changing the course of Alzheimer’s seemed impossible. Now, more than 150 experimental treatments are being tested in more than 190 trials worldwide. The pace of progress is accelerating, and with every new discovery, we move closer to a future where a cure could become a reality.”

Original Source
https://www.telegraph.co.uk/news/2026/11/19/stem-cells-injected-brain-alzheimers-patients-world-first/
Visit The Telegraph ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health